State and Demographic Variation in Use of Depot Antipsychotics by Medicaid Beneficiaries With Schizophrenia

The study used Medicaid Analytic Extract (MAX) data from 2007. MAX data include Medicaid-funded medical and pharmacy claims for every state and the District of Columbia. MAX is created from the eligibility and claims files that states submit to the Centers for Medicare and Medicaid Services. Variables in MAX are standardized to create comparable measures of service use across states. Fee-for-service data undergo an extensive quality review. However, at the time of this study, complete and reliable data on encounters provided by health maintenance organizations or behavioral health organizations were not available for all states.

This analysis included states with reliable fee-for-service or managed care encounter claims in 2007. The authors examined the completeness of MAX data for every state, described in detail elsewhere (5). Eighteen states with incomplete managed care data were excluded; five states were excluded because it was not possible to determine whether beneficiaries were enrolled in managed care, waiver programs, or private insurance; five states with missing medication data were excluded; and one state was missing mental health claims.

The study population included adults age 18 to 64 years who had a primary diagnosis of schizophrenia on at least one inpatient claim or two outpatient claims on different dates (6), who qualified for full Medicaid benefits because of disability for at least ten months in 2007, and who had no other health insurance, including Medicare. The analytic file included 102,884 beneficiaries meeting these criteria in 21 states and the District of Columbia.

Descriptive statistics were used to examine the receipt of depot antipsychotics (haloperidol decanoate [50 mg], fluphenazine decanoate, and risperidone Consta). Both National Drug Codes on pharmacy claims and J-codes on medical claims were used to identify depot antipsychotics, because Medicaid agencies may reimburse these medications through either the pharmacy program or the physician benefit. Given that this study was intended to describe patterns in the use of depot antipsychotics across states and beneficiary groups, we did not conduct tests of statistical significance.

Across the 21 states and the District of Columbia, a mean of 10% of beneficiaries with schizophrenia had at least one claim for a depot antipsychotic. Proportions ranged from 1.9% of beneficiaries in the District of Columbia to nearly 20.9% in Alabama (Table 1).

The racial distribution of depot antipsychotic recipients among the entire population of beneficiaries with schizophrenia was examined. In most states, a larger proportion of African Americans received depot antipsychotics. For example, in Alabama, African Americans were nearly twice as likely as Caucasians to receive depot antipsychotics (24.7% compared with 13.2%). This pattern of findings was similar across most states in the study, with the exception of California, Illinois, Iowa, and the six states in which the sample size was insufficient (sample size of <100 in any racial group).

In seven states, most recipients of depot antipsychotics were African American (Table 1). For example, 72% of beneficiaries who received depot antipsychotics in Alabama were African American. This pattern of findings was similar for Georgia, Illinois, Louisiana, Maryland, Mississippi, and North Carolina. Although these findings are driven in part by the fact that most Medicaid beneficiaries with schizophrenia in these states are African American, the underlying racial distribution of the population may not fully explain the pattern. In every state except California, Illinois, and Iowa, depot antipsychotic recipients were disproportionately African American, compared with the racial distribution of the Medicaid population with schizophrenia in each state.

Even in states where fewer than half of the beneficiaries who received depot antipsychotics were African American, African Americans were overrepresented among depot antipsychotic recipients (Table 1). For example, in Indiana, 37.4% of those who received depot antipsychotics were African American, which is 8.2 percentage points higher than what would be expected based on the racial distribution of the population with schizophrenia in that state. That is, if the racial distribution of depot antipsychotic recipients reflected the racial distribution of all beneficiaries with schizophrenia in Indiana, only 29.2% of depot antipsychotic users would be African American.

In most states, younger beneficiaries were slightly more likely to receive depot antipsychotics (roughly 12% of those ages 18–24 or 25–30 received depot antipsychotics, compared with 9%−10% for all other age groups). No differences were found by gender.

Relatively few Medicaid beneficiaries with schizophrenia received depot antipsychotics, but wide variation across states was found. Several possible explanations for this variation were not examined in this study because of data limitations. First, although all state Medicaid programs included in this study provided depot antipsychotics, variation by state in reimbursement arrangements or medication utilization controls may have influenced receipt of these medications. Second, because other studies have found that depot antipsychotics are often provided during or immediately after hospitalization (7,8), variation in receipt of these medications may reflect underlying hospitalization rates in the states. Finally, there may be state or regional differences in providers’ attitudes toward depot antipsychotics (9).

Other studies have found that African Americans are more likely than Caucasians to receive depot antipsychotics in hospitals (10), emergency rooms (11), and outpatient settings (12–15), and this study identified racial differences at the state level. Although the proportion of depot antipsychotic recipients who were African American was particularly high in some southern states, the disproportionate use of these medications among African Americans was present across states with both high and low levels of depot antipsychotic use and across states where African Americans made up both a high and low proportion of the Medicaid population with schizophrenia. Another explanation for the findings—one that could not be directly examined in this study—could be that depot antipsychotics were targeted to individuals with poorer antipsychotic adherence, a majority of whom could be African American. As reported elsewhere, in all but two states in this study, African Americans were more likely than Caucasians to have gaps in their antipsychotic refills (5). Nonetheless, the disproportionate use of these medications among the African-American population merits further investigation. It is possible that race serves as a proxy for some unmeasured characteristics, such as access to treatment, poverty, or other cultural or social factors. In addition, unique features of states, including rural geography or high poverty, may influence use of these medications, particularly in the southern states included in this study.

This study contributes information about the use of depot antipsychotics among a large and geographically diverse population of Medicaid beneficiaries. The findings should be interpreted in the context of several limitations. Not all states were included in the study because of data limitations described above. We could not measure receipt of depot antipsychotics not covered by Medicaid. Because of restrictions on the use of the data, this exploratory study could not examine sources of state or racial variation in use of these medications. Rather, this report is intended to identify opportunities for further inquiry and provide a foundation for future research.

The use of depot antipsychotics was found to differ across states. In many states, the racial distribution of those who received depot antipsychotics did not reflect the racial distribution of the state Medicaid population with schizophrenia. In several states, African Americans were the predominant recipients of depot antipsychotics. The findings underscore the need for Medicaid programs to monitor the use of depot antipsychotics and for further research to understand the sources of variation in use of these medications.

This work was conducted under contract HHSP23320095642WC/HHSP23337012T with the Office of the Assistant Secretary for Planning and Evaluation (ASPE), U.S. Department of Health and Human Services (DHHS). The authors appreciate the guidance of Richard Frank, Ph.D., John Drabek, Kirsten Beronio, J.D., James Verdier, J.D., and a technical advisory panel. The views and opinions expressed here are those of the authors and do not necessarily reflect the views, opinions, or policies of ASPE or DHHS.

The authors report no competing interests.